SCHEMBL359896

SCHEMBL359896

CCn1cc(-n2ccc(=O)c(COc3ccc4ncccc4c3)n2)cn1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EIF2AK4 Q9P2K8 1/20 0.41
MET P08581 2/20 0.40
MAPT P10636 6/20 0.39
RAB9A P51151 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PDE10A Q9Y233 1/20 0.38
SYK P43405 1/20 0.37
KDM4E B2RXH2 2/20 0.37
LMNA P02545 1/20 0.37
TNF P01375 1/20 0.36
MAPK1 P28482 1/20 0.36
NOD2 Q9HC29 1/20 0.36
NOD1 Q9Y239 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HTT P42858 2/20 0.36
ALDH1A1 P00352 3/20 0.35
RECQL P46063 1/20 0.35
NR2F2 P24468 2/20 0.35
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162668 0.89 MET (0.43) METMAPTRAB9ASMN1; SMN2PDE10A
SCHEMBL370955 0.86 MET (0.38) METMAPTKDM4ELMNAALDH1A1
SCHEMBL14916145 0.86 PPARG (0.37) EIF2AK4METMAPTSYKKDM4E
SCHEMBL371343 0.86 PDGFRB (0.45) METPDE10AMAPK1
SCHEMBL368322 0.84 PDGFRB (0.41) EIF2AK4METMAPK1
SCHEMBL359863 0.84 PDGFRB (0.34) EIF2AK4METMAPTKDM4ELMNA
SCHEMBL368757 0.84 MET (0.37) EIF2AK4MET
SCHEMBL14915761 0.84 MET (0.41) METALDH1A1
SCHEMBL367674 0.83
SCHEMBL10283523 0.83 MET (0.39) MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593107-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-05-22 EP claimed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US claimed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO claimed
EP-2593107-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-05-22 EP disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116231-A1 TYROSINE KINASE INHIBITORS ABL1, ERBB2, MET EIF2AK4 1037/4885MET 3/4885MAPT 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.